stoxline Quote Chart Rank Option Currency Glossary
Solid Biosciences Inc. (SLDB)
8.91  -0.73 (-7.57%)    07-17 16:00
Open: 9.52
High: 9.78
Volume: 416,100
Pre. Close: 9.64
Low: 8.5304
Market Cap: 342(M)
Technical analysis
2024-07-17 5:30:20 PM
Short term     
Mid term     
Targets 6-month :  11.98 1-year :  13.99
Resists First :  10.26 Second :  11.98
Pivot price 6.98
Supports First :  7.13 Second :  5.21
MAs MA(5) :  8.64 MA(20) :  6.83
MA(100) :  9.42 MA(250) :  6.43
MACD MACD :  0.2 Signal :  -0.2
%K %D K(14,3) :  80.4 D(3) :  80.1
RSI RSI(14): 61.7
52-week High :  15.05 Low :  1.8
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ SLDB ] has closed below upper band by 12.4%. Bollinger Bands are 51.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 9.79 - 9.84 9.84 - 9.89
Low: 8.42 - 8.47 8.47 - 8.52
Close: 8.82 - 8.91 8.91 - 8.99
Company Description

Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

Headline News

Tue, 16 Jul 2024
Solid Biosciences (NASDAQ:SLDB) Raised to Overweight at JPMorgan Chase & Co. - American Banking and Market News

Mon, 15 Jul 2024
Solid Biosciences up 10% following J.P. Morgan upgrade (NASDAQ:SLDB - Seeking Alpha

Mon, 15 Jul 2024
JPMorgan Chase & Co. Upgrades Solid Biosciences (NASDAQ:SLDB) to Overweight - MarketBeat

Mon, 15 Jul 2024
Solid Biosciences (NASDAQ:SLDB) Upgraded at JPMorgan Chase & Co. - Defense World

Mon, 01 Jul 2024
Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mon, 01 Jul 2024
Solid Biosciences Joins the Russell 3000® Index - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 38 (M)
Shares Float 13 (M)
Held by Insiders 0.8 (%)
Held by Institutions 94.5 (%)
Shares Short 904 (K)
Shares Short P.Month 929 (K)
Stock Financials
EPS -3.94
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 5.57
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -26 %
Return on Equity (ttm) -45.8 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.53
Qtrly Earnings Growth 0 %
Operating Cash Flow -91 (M)
Levered Free Cash Flow -63 (M)
Stock Valuations
PE Ratio -2.27
PEG Ratio 0
Price to Book value 1.59
Price to Sales 0
Price to Cash Flow -3.75
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android